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We read with interest the recent review on chronic
obstructive pulmonary disease (COPD) and lung cancer by
Potton et al.1 We agree with their conclusion that COPD and
lung cancer are closely associated andoutline here a possible
pathogenic link that not only explains the basis of this rela-
tionship but also the potential for chemopreventive therapy.
As Potton et al. point out, only 10e20% of smokers
develop COPD or lung cancer. Not only do the epidemio-
logical studies show that COPD (i.e. spirometric evidence of
airflow obstruction) is the most important risk factor for
lung cancer, seen in both smokers and non-smokers,1 it
commonly pre-dates lung cancer in 50e90% of cases.2 This
frequency is dependent on both criteria for COPD (spiro-
metric definition and/or CT evidence of emphysema) and
the source population of the lung cancer cases. The key
conclusion from these studies is that smokers susceptible to
COPD are up to five fold more susceptible to lung cancerExaggerated
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Figure 1 Proposed relationship between smoking, COPD and
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doi:10.1016/j.rmed.2009.11.025than smokers with normal lung function. Such a finding
supports the view that FEV1 is a biomarker of wider respi-
ratory risk from smoking (i.e. a ‘‘barometer’’ identifying
susceptible smokers).3
We agree with Potton et al. that the pulmonary inflam-
mation and the lung matrix remodelling that underlies
COPD, maybe important precursors to lung cancer. We
suggest this relationship is much like that which exists
between obesity and type 2 diabetes, where one disease is
pathogenically related to the other. In this regard the
exaggerated release of growth factors and matrix metal-
loproteinases from matrix remodelling, maybe promoting
malignant transformation in the respiratory epithelium.4,5
This process is called epithelialemesenchymal transition
(EMT) and has been previously implicated in many cancers
including lung cancer.4e6 In this process, bronchial epithe-
lial cell (BEC) integrity and function is disrupted by matrix
remodelling and growth factor release that underlies COPD
(such as TGFB and MMPs) and together promote EMT
(Fig. 1). The effect of growth factors on EMT has been
shown to be promoted by collagen 1, directly linking lung
remodelling (COPD) with EMT.6 In animal models, the
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Letter to the Editor 759eg Ras, Rho and Rac) have been linked to the development
of lung cancer, with NF-kB mediating this effect in a COPD
mouse model.5,7 In vitro studies show that inhibition of
GTPases can reverse EMT and restore epithelium to its
normal morphology.8
Although several pathological pathways are likely to be
involved in the development of COPD and EMT, the majority
are mediated intracellularly by GTPases.4,5,9 These signalling
molecules require isoprenylation to be active and are critical
for cellular function through up-regulating effects on tran-
scription binding factors such as NF-kB and AP-1 central to
gene expression in COPD9 and lung cancer development.5 If
EMT is an important pre-malignant event, then the inflam-
mation and matrix remodelling processes that lead to COPD
may also lead to lung cancer thereby explaining this close
relationship inanoverlapping groupof genetically susceptible
smokers (Fig. 1).1,9,10 If this were true, then any pharmaco-
logical agent that could attenuate the inflammatory and
matrix remodelling processes underlying COPD might also
reduce the risk (and development) of lung cancer.4 In this
regard it is interesting that Potton et al. implicate the
inflammatory action of IL-6 in COPD and lung cancer and its
down-streameffectonStat3.1 Interleukin-6hasbeenstrongly
implicated in both COPD11 and lung cancer.12 It has recently
been shown that anti-IL-6 based treatment suppresses
tumorigenesis.13 In a recently published review of the phar-
macological actions of statins in COPD,4 we present data from
both observational studies and pre-clinical studies showing
that statinsmay inhibit thetendency toCOPDand lungcancer.
In addition we suggest that the statin effect occurs through
known inhibitory action on GTPase isoprenylation with
subsequent down regulation of IL-6 activity4 through inhibi-
tion of Stat314,15 and reversal of EMT.16 We conclude that not
only is COPD closely linked to lung cancer through epidemio-
logical studies, genetic studies and pathogenic pathways,
they may also both benefit from the chemopreventive
potential of anti-inflammatory therapies such as statins.4
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